Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043316 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Vikrant Rai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Research, Western University of Health Sciences, 309 E. Second Street, Pomona, CA 91766, USA. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Esophageal cancer (EC) is the deadliest cancer worldwide, with a 92% annual mortality rate per incidence. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of ECs, with EAC having one of the worst prognoses in oncology. Limited screening techniques and a lack of molecular analysis of diseased tissues have led to late-stage presentation and very low survival durations. The five-year survival rate of EC is less than 20%. Thus, early diagnosis of EC may prolong survival and improve clinical outcomes. Cellular and molecular biomarkers are used for diagnosis. At present, esophageal biopsy during upper endoscopy and histopathological analysis is the standard screening modality for both ESCC and EAC. However, this is an invasive method that fails to yield a molecular profile of the diseased compartment. To decrease the invasiveness of the procedures for diagnosis, researchers are proposing non-invasive biomarkers for early diagnosis and point-of-care screening options. Liquid biopsy involves the collection of body fluids (blood, urine, and saliva) non-invasively or with minimal invasiveness. In this review, we have critically discussed various biomarkers and specimen retrieval techniques for ESCC and EAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Research, Western University of Health Sciences, 309 E. Second Street, Pomona, CA 91766, USA.
- Department of Research and Development, Stella Diagnostics, Inc., Salt Lake City, UT 84104, USA.
- ProPhase Labs, Inc., Garden City, NY 11530, USA.
ORCID-Profile: Vikrant Rai, Devendra K Agrawal
Förderung
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Rai, V., Abdo, J., & Agrawal, D. K. (2023). Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043316
Vancouver
Rai V, Abdo J, Agrawal DK. Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043316
BibTeX
@article{Rai2023,
author = {Rai, Vikrant and Abdo, Joe and Agrawal, Devendra K},
title = {Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043316}
}
EUVIMED